Gepirone

Gepirone
Clinical data
Trade namesExxua
Other namesBMY-13805; MJ-13805; ORG-13011
Routes of
administration
By mouth
Drug classSerotonin 5-HT1A receptor partial agonist; Antidepressant
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability14–17%
Protein binding72%
MetabolismCYP3A4
Metabolites3'-OH-gepirone; 1-(2-Pyrimidinyl)piperazine
Elimination half-lifeIRTooltip Instant release: 2–3 hours
ERTooltip Modified-release dosage: 5 hours
ExcretionUrine: 81%
Feces: 13%
Identifiers
  • 4,4-Dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H29N5O2
Molar mass359.474 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)CC(C)(C)C1)CCCCN3CCN(c2ncccn2)CC3
  • InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3 checkY
  • Key:QOIGKGMMAGJZNZ-UHFFFAOYSA-N checkY
  (verify)

Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally.

Side effects of gepirone include dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion). Gepirone acts as a partial agonist of the serotonin 5-HT1A receptor. An active metabolite of gepirone, 1-(2-pyrimidinyl)piperazine, is an α2-adrenergic receptor antagonist. Gepirone is a member of the azapirone group of compounds.

Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. It was approved for the treatment of major depressive disorder in the United States in September 2023. This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness.